[Current insights into the modern treatment of decompensated heart failure].
Treatment of DHF is a challenge even for the experienced physician. Advances in research have brought new treatment options that are helping change paradigms. The available evidence suggests that new drugs like levosimendan and nesiritide will assume relevant positions as alternatives or complements to treatment with traditional inotropic drugs like dobutamine. The physician responsible for treating these patients should learn how to use the best available evidence, in order to tailor treatment with safety and efficacy.
Vilas-Boas
Fábio
F
Hospital Espanhol, Cardiology Division, Salvador, BA, Brasil. fabiovboas@cardiol.br
Follath
Ferenc
F
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000465:Algorithms; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D014665:Vasodilator Agents / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D002316:Cardiotonic Agents; D004232:Diuretics; D014665:Vasodilator Agents